Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting

Phase 1

Phase 2

M3814 with RadiotherapyTesting the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04172532

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Stage III Pancreatic Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Hypofractionated Radiation Therapy

Magnetic Resonance Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-25.